T cell receptors specific for a mutant form of the ret oncogene and uses thereof
AssigneeProvidence Health & Services - Oregon
InventorsEric Tran, Yi-Ping Shih
Life of this patent
Estimating the term…
Abstract
Isolated T cell receptors (TCRs) that specifically recognize a peptide derived from a mutant form of RET (M918T) are described. The TCRs include an alpha chain variable region and a beta chain variable region having the complementarity determining regions (CDRs) of an alpha chain variable region and beta chain variable region of a TCR isolated from a patient with sporadic MTC whose tumor harbored the RET M918T mutation. Cells, such as T cells, expressing the isolated TCRs can be used to treat cancers expressing M918T RET, such as medullary thyroid cancer (MTC).
Claims33
An isolated T cell receptor (TCR) having antigenic specificity for a mutant form of the rearranged during transfection (RET) proto-oncogene with a methionine to threonine substitution at position 918 of SEQ ID NO:
- 11, wherein the TCR comprises:
- (a) an alpha chain variable region comprising a complementarity determining region 1 (CDR1), a CDR2 and a CDR3, wherein the amino acid sequences of the CDR1, CDR2 and CDR3 respectively comprise:
- (i) residues 46-51, 69-75 and 110-120 of SEQ ID NO:
- 2;
- (ii) residues 47-53, 71-78 and 113-123 of SEQ ID NO:
- 6;
- or
- (iii) residues 53-58, 76-82 and 117-129 of SEQ ID NO:
- 19;
- and
- (b) a beta chain variable region comprising a CDR1, a CDR2 and a CDR3, wherein the amino acid sequences of the CDR1, CDR2 and CDR3 respectively comprise:
- (i) residues 46-50, 68-72 and 111-119 of SEQ ID NO:
- 4;
- (ii) residues 46-49, 67-72 and 111-123 of SEQ ID NO:
- 8;
- or
- (iii) residues 46-50, 68-73 and 112-126 of SEQ ID NO:
- 21.
4-7. (canceled)
11-14. (canceled)
17-18. (canceled)
(canceled)
(canceled)
32-33. (canceled)
41-42. (canceled)
Dependencies are inferred from the claim text.